RETN and ovarian cancer: Current reports indicate that abnormal expression of resistin and its receptors are found in the course of many malignancies, particularly breast cancer, esophageal squamous cell carcinoma, gastric cancer, endometrial adenocarcinoma and ovarian cancer [183,184,185].